BRPI0919174A2 - composições imunocontraceptivas recombinantes à base do vírus da raiva e métodos de uso - Google Patents

composições imunocontraceptivas recombinantes à base do vírus da raiva e métodos de uso

Info

Publication number
BRPI0919174A2
BRPI0919174A2 BRPI0919174A BRPI0919174A BRPI0919174A2 BR PI0919174 A2 BRPI0919174 A2 BR PI0919174A2 BR PI0919174 A BRPI0919174 A BR PI0919174A BR PI0919174 A BRPI0919174 A BR PI0919174A BR PI0919174 A2 BRPI0919174 A2 BR PI0919174A2
Authority
BR
Brazil
Prior art keywords
methods
rabies virus
recombinant rabies
compositions
based immunocontraceptive
Prior art date
Application number
BRPI0919174A
Other languages
English (en)
Inventor
Charles Rupprecht
Xianfu Wu
Original Assignee
Government Of The Us Secretary Of The Dept Of Health And Human Services Ct S For Disease Control And
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The Us Secretary Of The Dept Of Health And Human Services Ct S For Disease Control And filed Critical Government Of The Us Secretary Of The Dept Of Health And Human Services Ct S For Disease Control And
Publication of BRPI0919174A2 publication Critical patent/BRPI0919174A2/pt
Publication of BRPI0919174B1 publication Critical patent/BRPI0919174B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0919174-7A 2008-09-17 2009-08-20 vírus da raiva recombinante, composição imunogênica e seu uso BRPI0919174B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9774808P 2008-09-17 2008-09-17
US61/097,748 2008-09-17
PCT/US2009/054502 WO2010033337A1 (en) 2008-09-17 2009-08-20 Rabies virus-based recombinant immunocontraceptive compositions and methods of use

Publications (2)

Publication Number Publication Date
BRPI0919174A2 true BRPI0919174A2 (pt) 2015-12-15
BRPI0919174B1 BRPI0919174B1 (pt) 2020-11-17

Family

ID=41217642

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919174-7A BRPI0919174B1 (pt) 2008-09-17 2009-08-20 vírus da raiva recombinante, composição imunogênica e seu uso

Country Status (7)

Country Link
US (1) US8524247B2 (pt)
EP (1) EP2344193B1 (pt)
CN (1) CN102159240B (pt)
BR (1) BRPI0919174B1 (pt)
CA (1) CA2736604C (pt)
WO (1) WO2010033337A1 (pt)
ZA (1) ZA201102006B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011163446A2 (en) * 2010-06-24 2011-12-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Pan-lyssavirus vaccines against rabies
WO2014052693A2 (en) 2012-09-29 2014-04-03 The Trustees Of The University Of Pennsylvania Veterinary composition and methods for non-surgical neutering and castration
US20140271716A1 (en) * 2013-03-15 2014-09-18 Ark Sciences, Inc. Intra-testicular Injection of Immunogens
WO2014189654A1 (en) * 2013-05-23 2014-11-27 Thomas Jefferson University Co-immunization with attenuated rabies virus and non-rabies antigen
WO2022200762A1 (en) * 2021-03-26 2022-09-29 Sporomex Limited Methods for the extraction of dispersible microcapsules (immunocontraception)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
WO1988005308A1 (en) 1987-01-14 1988-07-28 Commonwealth Scientific And Industrial Research Or Anti reproductive hormone
US5484592A (en) 1989-03-23 1996-01-16 Stitching Centraal Diergeneeskundig Instituut Peptide, immunogenic composition and vaccine or medicinal preparation: a method of immunising a mammal against LHRH, and a method of improving the meat quality of pigs
ATE140972T1 (de) 1989-08-25 1996-08-15 Biotech Australia Pty Ltd Fusionsproteine bestehend aus tratp und mindestens einem lhrh-analog
AU4303493A (en) 1992-06-05 1994-01-04 University Of Dalhousie Use of zona pellucida glycoproteins for immunocontraception
DE69333610D1 (de) 1992-11-09 2004-10-07 Zonagen Inc Methoden für die immunoempfängnisverhütung
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US5885966A (en) 1995-06-07 1999-03-23 Dlo Instituut Voor Dierhouderij En Diergezondheid Peptide, immunogenic composition and vaccine or medical preparation, a method to immunise animals against the hormone LHRH, and analogs of the LHRH tandem repeat peptide and their use as vaccine
ATE286511T1 (de) * 1999-02-17 2005-01-15 Pfizer Prod Inc Fusionsproteine mit trägern welche eine doppelte immunantwort induzieren
WO2001070932A2 (en) 2000-03-23 2001-09-27 Thomas Jefferson University Genetically engineered rabies recombinant vaccine for immunization of stray dogs and wildlife
EP1434862A4 (en) * 2001-07-20 2005-04-06 Univ Georgia Res Found ATTENUATED TOLL WUTVIRUS WITH NUCLEOPROTEIN MUTATION AT THE PHOSPHORYLATION CENTER FOR VACCINATION AGAINST FOLLOW-UP AND GENE THERAPY IN THE CNS
CA2463090C (en) * 2001-10-10 2012-06-12 Thomas Jefferson University Recombinant rabies vaccine and methods of preparation and use
US7056515B2 (en) 2002-02-08 2006-06-06 Immunovaccine Technologies Inc. Antigens for immunocontraception
WO2003089590A2 (en) * 2002-04-16 2003-10-30 Vaxin, Inc. TRANSIENT AND/OR PERMANENT MODIFICATION OF SEXUAL BEHAVIOR AND/OR FERTILITY USING RECOMBINANT CHIMERIC GnRH
WO2004026024A2 (en) 2002-09-20 2004-04-01 The United States Of America As Represented By The Secretary Of Agriculture Vaccine compositions and adjuvant
EP1768697B1 (en) * 2004-07-12 2010-06-02 Thomas Jefferson University Recombinant rabies virus compositions
CA2943039C (en) * 2005-10-14 2018-11-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Rabies virus compositions and methods

Also Published As

Publication number Publication date
CN102159240B (zh) 2014-12-24
WO2010033337A8 (en) 2011-04-14
US8524247B2 (en) 2013-09-03
BRPI0919174B1 (pt) 2020-11-17
WO2010033337A1 (en) 2010-03-25
EP2344193B1 (en) 2013-10-02
CN102159240A (zh) 2011-08-17
CA2736604A1 (en) 2010-03-25
ZA201102006B (en) 2014-06-25
US20110165189A1 (en) 2011-07-07
CA2736604C (en) 2017-01-03
EP2344193A1 (en) 2011-07-20

Similar Documents

Publication Publication Date Title
SMT201600388B (it) Ligandi leganti opsina, composizioni e metodi d'uso
BRPI0922708A2 (pt) peptídeos mini-hepcidina e métodos de uso do mesmo
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0908936A2 (pt) vacinas de flavivírus de replicação defeituosa e vetores de vacina
DK2504353T4 (da) Lipopeptidsammensætninger og tilsvarende fremgangsmåder
BRPI1005670A2 (pt) composições adjuvantes e métodos de uso
BRPI0912703A2 (pt) composições imuno-moduladoras e métodos para uso dessas
DK2220116T3 (da) Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
EP2496691A4 (en) THERAPEUTIC NUCLEASE COMPOSITIONS AND METHOD THEREFOR
BRPI1008280A2 (pt) Formulações prebióticas e métodos mde uso
BRPI0814594A2 (pt) Composições e métodos adjuvantes de antígeno
BRPI0910852A2 (pt) composições contendo lipídios e métodos de uso das mesmas
PL2356462T3 (pl) Kompozycje anty-CXCR1 oraz sposoby
BRPI0909770A2 (pt) Vacina, e, kit
DK3156069T3 (da) Sammensætninger, fremgangsmåder, og kits til fremkaldelse af et immunrespons
DK2254569T3 (da) Ginsenosid-sammensætninger af protopanaxadiol-typen og anvendelser deraf
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
FI20096058A0 (fi) Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
BRPI0914300A2 (pt) composições e métodos para imunogenicidade intensificada de somatostatina
PL2349314T3 (pl) Formulacje liofilizowanego rekombinowanego VWF
EP2222344A4 (en) VACCINATE COMPOSITIONS WITH DENDRITIC CELLS AND THEIR USE
BRPI1006863A2 (pt) composições de vacina e plasmodium purificado
BRPI0923513A2 (pt) método e composições para uso de uma vacina de coccidiose
DK2337521T3 (da) Midlertidig embolibeskyttelsesindretning
BRPI0919485A2 (pt) vacinas, antígenos, composições de plasmodium e métodos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: EXTINTA A PATENTE, NOS TERMOS DO ARTIGO 86, DA LPI, E ARTIGO 14 DA PORTARIA 52/2023, REFERENTE AO NAO RECOLHIMENTO DA 16A RETRIBUICAO ANUAL (VIDE PARECER).

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2841 DE 17-06-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.